SNY (Sanofi) Other Net Income (Loss) : $129 Mil (TTM As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Other Net Income (Loss)?

Sanofi's Other Net Income (Loss) for the six months ended in Dec. 2024 was $143 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was $129 Mil.

Sanofi's quarterly Other Net Income (Loss) declined from Dec. 2023 ($277 Mil) to Jun. 2024 ($-14 Mil) but then increased from Jun. 2024 ($-14 Mil) to Dec. 2024 ($143 Mil).

Sanofi's annual Other Net Income (Loss) declined from Dec. 2022 ($483 Mil) to Dec. 2023 ($220 Mil) and declined from Dec. 2023 ($220 Mil) to Dec. 2024 ($130 Mil).

Sanofi Other Net Income (Loss) Historical Data

The historical data trend for Sanofi's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Other Net Income (Loss) Chart

Sanofi Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

436.74

44.07

483.05

220.28

129.84

Sanofi Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															421.61	-56.34	276.99	-14.00	143.46

Sanofi Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $129 Mil.

Sanofi Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Sanofi's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SAN1:Mexico SNY N:Mexico 1SAN:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, Avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.